Low frequency ranibizumab versus dexamethasone implant for macular oedema secondary to branch retinal vein occlusion

Clinical and Experimental Optometry

Volumn 101, Issue 1, 2018, Pages 116-122

  Yuksel, Bora ^a   Karti, Omer ^a   Celik, Ozan ^a   Kerci, Suleyman Gokhan ^a   Kusbeci, Tuncay ^a  

^a UNIVERSITY OF HEALTH SCIENCES   (Turkey)

Author keywords

branch retinal vein occlusion; dexamethasone; grid laser; macular oedema; ranibizumab

Indexed keywords

ANGIOGENESIS INHIBITOR; DEXAMETHASONE; GLUCOCORTICOID; RANIBIZUMAB;

ACOUSTIC MICROSCOPY; COMPLICATION; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG IMPLANT; FEMALE; FOLLOW UP; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MALE; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; RETINA VEIN OCCLUSION; RETROSPECTIVE STUDY; TIME FACTOR; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG IMPLANTS; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MICROSCOPY, ACOUSTIC; MIDDLE AGED; RANIBIZUMAB; RETINAL VEIN OCCLUSION; RETROSPECTIVE STUDIES; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME;

EID: 85038034281     PISSN: 08164622     EISSN: 14440938     Source Type: Journal    
DOI: 10.1111/cxo.12586     Document Type: Article

References (28)

1. Channa R, Smith M, Campochiaro PA. Treatment of macular edema due to retinal vein occlusions. Clin Ophthalmol 2011; 5: 705–713.
2. Glanville J, Patterson J, McCool R et al. Efficacy and safety of widely used treatments for macular oedema secondary to retinal vein occlusion: a systematic review. BMC Ophthalmol 2014; 14: 7.
3. Hayreh SS. Ocular vascular occlusive disorders: Natural history of visual outcome. Prog Retin Eye Res 2014; 41: 1–25.
4. Berger AR, Cruess AF, Altomare F et al. Optimal treatment of retinal vein occlusion: Canadian expert consensus. Ophthalmologica 2015; 234: 6–25.
5. Campochiaro PA, Heier JS, Feiner L et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010; 117: 1102–1112.
6. Dugel PU, Capone A Jr, Singer MA et al. Two or more dexamethasone intravitreal implants in treatment-naïve patients with macular edema due to retinal vein occlusion: subgroup analysis of a retrospective chart review study. BMC Ophthalmol 2015; 5: 118.
7. The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 1984; 98: 71–82.
8. Brown DM, Campochiaro PA, Bhisitkul RB et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 2011; 118: 1594–1602.
9. Haller JA, Bandello F, Belfort R Jr et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010; 117: 1134–1146.
10. Haller JA, Bandello F, Belfort R Jr et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 2011; 118: 2453–2460.
11. Hattenbach LO, Feltgen N, Bertelmann T et al. Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B). Acta Ophthalmol 2017; https://doi.org/10.1111/aos.13381.
12. Mayer WJ, Hadjigoli A, Wolf A et al. Comparison of intravitreal dexamethasone implant versus intravitreal ranibizumab as a first-line treatment of macular oedema due to retinal vein occlusion. Klin Monbl Augenheilkd 2015; 232: 1289–1296.
13. Nghiem BS, Fajnkuchen F, Buffet M et al. Intravitreal ranibizumab and/or dexamethasone implant for macular edema secondary to retinal vein occlusion. Ophthalmologica 2014; 232: 216–222.
14. Proença Pina J, Turki K, Labreuche J et al. Efficacy and safety in retinal vein occlusion treated with at least three consecutive intravitreal dexamethasone implants. J Ophthalmol 2016; 6016491.
15. Moisseiev E, Goldstein M, Waisbourd M et al. Long-term evaluation of patients treated with dexamethasone intravitreal implant for macular edema due to retinal vein occlusion. Eye (Lond) 2013; 27: 65–71.
16. Adelman RA, Parnes AJ, Bopp S et al. Strategy for the management of macular edema in retinal vein occlusion: the European VitreoRetinal Society macular edema study. Biomed Res Int 2015; 2015: 870987.
17. Thom HH, Capkun G, Nixon RM et al. Indirect comparisons of ranibizumab and dexamethasone in macular oedema secondary to retinal vein occlusion. BMC Med Res Methodol 2014; 14: 140.
18. Regnier SA, Larsen M, Bezlyak V et al. Comparative efficacy and safety of approved treatments for macular oedema secondary to branch retinal vein occlusion: a network meta-analysis. BMJ Open 2015; 5: e007527.
19. Thach AB, Yau L, Hoang C et al. Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trials. Ophthalmology 2014; 121: 1059–1066.
20. Brown DM, Campochiaro PA, Bhisitkul RB et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 2011; 118: 1594–602.
21. Unsal E, Eltutar K, Sultan P et al. Efficacy and safety of Pro Re Nata regimen without loading dose ranibizumab injections in retinal vein occlusion. Pak J Med Sci 2015; 31: 510–515.
22. Farinha C, Marques JP, Almeida E et al. Treatment of retinal vein occlusion with ranibizumab in clinical practice: longer-term results and predictive factors of functional outcome. Ophthalmic Res 2015; 55: 10–18.
23. Altunel O, Duru N, Goktas A et al. Evaluation of foveal photoreceptor layer in eyes with macular edema associated with branch retinal vein occlusion after Ozurdex treatment. Int Ophthalmol 2017; 37: 333–339.
24. Lam WC, Albiani DA, Yoganathan P et al. Real-world assessment of intravitreal dexamethasone implant (0.7 mg) in patients with macular edema: the CHROME study. Clin Ophthalmol 2015; 9: 1255–1268.
25. Narayanan R, Panchal B, Stewart MW et al. Grid laser with modified pro re nata injection of bevacizumab and ranibizumab in macular edema due to branch retinal vein occlusion: MARVEL report no 2. Clin Ophthalmol 2016; 10: 1023–1029.
26. Pielen A, Mirshahi A, Feltgen N et al. Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES): six-month results of a prospective randomized clinical trial. Acta Ophthalmol 2015; 93: e29–37.
27. Rezar S, Eibenberger K, Bühl W et al. Anti-VEGF treatment in branch retinal vein occlusion: a real-world experience over 4 years. Acta Ophthalmol 2015; 93: 719–725.
28. Groneberg T, Trattnig JS, Feucht N et al. Morphologic patterns on spectral-domain optical coherence tomography (SD-OCT) as a prognostic ındicator in treatment of macular edema due to retinal vein occlusion. Klin Monbl Augenheilkd 2016; 233: 1056–1062.